Current Open Trials
CC# 21708 (Fong, Lawrence) - A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Learn more
CC# 22705 (Keenan, Bridget) - A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Learn more
CC# 22703 (Oh, David) - A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Learn more
CC# 21702 (Fong, Lawrence) - An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Learn more
CC# 227011 (Keenan, Bridget) - A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Learn more
CC# 23706 (Keenan, Bridget) - A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
Learn more
CC# 237011 (Keenan, Bridget) - A First-in-Human Phase I Study of ATG-031 in Patients with Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Learn more
CC# 237012 (Keenan, Bridget) - A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent HEpatocellular CarciNomA: ATHENA
Learn more